Koen SandraBelgium

Biotech drugs, once considered a risky and nearly impossible route to explore, are today dominating the pharma landscape. In the footsteps of the biotech pioneers walking this bumpy road, our chromatographic community rose to the challenge and sharpened the analytical toolbox. Throughout the years we have seen products become increasingly complex and witnessed analytics becoming more and more performant. This talk will reflect on the recent advances in the analysis of biologics; from the coupling of historical incompatible chromatographic methods with mass spectrometry, to the combination of ever more separation modes in multidimensional set-ups and the implementation of chemical and enzymatic reactors in the flow path for primary and higher order structural assessment.